ストックスクリーナーアプリを入手
2.32
0.87%
0.02
Scpharmaceuticals Inc (SCPH) 最新ニュース
Market Cool On scPharmaceuticals Inc.'s (NASDAQ:SCPH) Revenues Pushing Shares 30% Lower - simplywall.st
Charles Schwab Investment Management Inc. Acquires 26,964 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
Bank of New York Mellon Corp Raises Stock Position in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
scPharmaceuticals stock hits 52-week low at $2.73 By Investing.com - Investing.com South Africa
scPharmaceuticals stock hits 52-week low at $2.73 - Investing.com India
Maxim Group Cuts scPharmaceuticals (NASDAQ:SCPH) Price Target to $12.00 - Defense World
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2024 Earnings Call Transcript - Insider Monkey
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Report Preview: Wh - GuruFocus
ScPharmaceuticals outlines FUROSCIX expansion strategy with CKD launch in April 2025 - MSN
Optimistic Buy Rating for scPharmaceuticals Amid Strong Q4 Results and Promising Developments - TipRanks
Analyst Expectations For scPharmaceuticals's Future - Benzinga
Maxim Adjusts Price Target on scPharmaceuticals to $12 From $20, Keeps Buy Rating - Marketscreener.com
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance
Earnings call transcript: SC Pharmaceuticals Q4 2024 beats EPS forecast - Investing.com India
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Call Highlights: R - GuruFocus
scPharmaceuticals Reports Strong Revenue Growth in 2024 - TipRanks
Earnings call transcript: SC Pharmaceuticals Q4 2024 beats EPS forecast By Investing.com - Investing.com Australia
scPharmaceuticals Inc. SEC 10-K Report - TradingView
ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
scPharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
scPharmaceuticals Inc (SCPH) Q4 Earnings: EPS Misses, Revenue Be - GuruFocus
SCPHARMACEUTICALS Earnings Results: $SCPH Reports Quarterly Earnings - Nasdaq
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Earnings Scheduled For March 19, 2025 - Benzinga
SCPHARMACEUTICALS Earnings Preview: Recent $SCPH Insider Trading, Hedge Fund Activity, and More - Nasdaq
ScPharma Eyes New Frontiers For Furoscix - RTTNews
scPharmaceuticals - The Pharma Letter
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025 - The Manila Times
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, ... - Post Register
scPharmaceuticals Readies Major Financial Update: Q4 and Full Year Results Coming March 19 - Stock Titan
Breakthroughs in Hyperkalemia DrugsMarket Opportunities - openPR
Scpharmaceuticals at Leerink’s Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by Rhumbline Advisers - Defense World
scPharmaceuticals (SCPH) to Release Earnings on Wednesday - Armenian Reporter
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD - Yahoo
H.C. Wainwright maintains Buy on scPharmaceuticals stock, $18 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on scPharmaceuticals stock, $18 target - Investing.com India
Strategic Market Expansion and Strong Sales Foundation Drive Buy Rating for scPharmaceuticals - TipRanks
HC Wainwright Cuts Earnings Estimates for scPharmaceuticals - Defense World
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease - The Manila Times
ScPharmaceuticals Says US FDA Approves Application to Expand Use of Furoscix -March 06, 2025 at 05:42 pm EST - Marketscreener.com
FDA Approves Expansion for Furosemide Injection to Treat Edema In Patients With CKD - Pharmacy Times
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the ... - The Bakersfield Californian
FUROSCIX Scores Crucial FDA WinNew CKD Treatment Could Transform Patient Care - StockTitan
SCPH stock touches 52-week low at $3.07 amid market challenges By Investing.com - Investing.com South Africa
SCPH stock touches 52-week low at $3.07 amid market challenges - Investing.com India
FY2029 Earnings Forecast for SCPH Issued By HC Wainwright - Defense World
ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy? - Nasdaq
scPharmaceuticals (SCPH) Projected to Post Quarterly Earnings on Wednesday - Defense World
A look into scPharmaceuticals Inc (SCPH)’s deeper side - SETE News
scPharmaceuticals (NASDAQ:SCPH) Receives “Buy” Rating from HC Wainwright - Defense World
ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates - MSN
Week Ahead (Oct.3Oct.7): Data Readouts, FDA Decision (TCDA, RLMD, SCPH...) - RTTNews
Certara, Inc. (CERT) Surpasses Q4 Earnings and Revenue Estimates - MSN
3.01%
大文字化:
|
ボリューム (24 時間):